IRD

Opus Genetics, Inc.

NasdaqCM · Healthcare

$4.07

-0.49% today

last filing 2026-05-18Pro sees filings in ~15 min

Price

hover · 4 moves explained

2 buys2 sells19 8-K

Prices distorted

Reverse-split 3×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what IRD ever actually traded at. The drop is real, but those huge old numbers aren't.

Analyst consensus

Strong Buy

$10.56target+159.4%vs $4.07 today

$8.00 low today target$16.00 high

18 analysts · ~12-month consensus · as of Jul 7. Relayed analyst opinion, which tends to run optimistic — not our forecast or advice.

Earnings

Beat 1 of last 4

Earnings per share · actual vs forecast

Q2 '25+53.8%

−$0.12

exp −$0.26

Q3 '25-92.3%

−$0.25

exp −$0.13

Q4 '25

−$0.21

exp −$0.10

Q1 '26

−$0.75

exp −$0.14

Type	Date	Insider	Title	Of stake	Shares	Price	Value
Sell	2026-05-20	Foundation Fighting Blindness Retinal Degeneration Fund	Director	—Direct	1,700,000	$4.35	$7.39M
Tax	2026-02-17	Jayagopal Ashwath	Chief Scientific & Dev. Ofc.	—Direct	5,313	$3.39	$18.0K
Grant	2026-01-26	YERXA BENJAMIN R	President	—Direct	400,000	—	—
Grant	2026-01-26	SCHACHLE JOSEPH K	Chief Operating Officer	—Direct	250,000	—	—
Grant	2026-01-26	Zaremba Rabourn Amy	Head of Fin. Quality Assurance	—Direct	86,500	—	—

Sell

Foundation Fighting Blindness Retinal Degeneration Fund

Director · 2026-05-20

$7.39M

1,700,000 @ $4.35

Tax

Jayagopal Ashwath

Chief Scientific & Dev. Ofc. · 2026-02-17

$18.0K

5,313 @ $3.39

Grant

YERXA BENJAMIN R

President · 2026-01-26

—

400,000 shares

Grant

SCHACHLE JOSEPH K

Chief Operating Officer · 2026-01-26

—

250,000 shares

Grant

Zaremba Rabourn Amy

Head of Fin. Quality Assurance · 2026-01-26

—

86,500 shares

19 more transactions on ProFull insider transaction history is a Pro feature.

Upgrade →